NCT07424027 is a NA clinical trial of MRI Contrast in Multiple Sclerosis, sponsored by The Cleveland Clinic.

Who is sponsoring NCT07424027?

NCT07424027 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT07424027?

Interventions in NCT07424027: MRI Contrast.

What condition does NCT07424027 study?

NCT07424027 studies Multiple Sclerosis.

Is NCT07424027 still recruiting?

NCT07424027 is currently recruiting now. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT07424027

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Central Vein Sign in Multiple Sclerosis Extension Study

Recruiting now NA Last updated 20 February 2026

What this trial tests

NA trial testing MRI Contrast in Multiple Sclerosis in 40 participants. Currently enrolling.

Timeline

7 October 2025

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	7 October 2025
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	3 locations across United States

Drugs / interventions tested

MRI Contrast — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

The Cleveland Clinic

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and evaluation of treatment response for MS. The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are two biomarkers that have shown promise in improving diagnostic accuracy for MS. The goal of this study is to provide pilot information on the long-term performance of the CVS and PRL to help diagnose and follow people with MS. The study will follow 40 participants over 48 months to determine if the CVS and PRL help make a diagnosis of MS and how they can be used to follow people with MS. The study will also examine how PRL and CVS change over 48 months. The results of this pilot study will inform the development of a grant application to extend 5-year follow-up for all 420 participants of the CAVS-MS study. The study will use high-resolution T2\*-weighted MRI to detect the CVS and PRLs. An MRI of the brain with contrast will be used to examine CVS, PRL and longitudinal analysis of lesions that slowly grow over time (slowly expanding lesions \[SELs\]). The results of this study have the potential to improve the accuracy of diagnosing and treating MS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI Contrast

Trials testing the same drug.

NCT07007208 — Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk · Phase 2 · not yet recruiting
NCT06743347 — Dynamic Measurement of Cerebrospinal Fluid in Healthy Subjects: Pilot Study · NA · completed
NCT06617624 — Magnetic Resonance Imaging Development for High Resolution Atrial Structural and Functional Characterization · not yet recruiting
NCT02550366 — Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI · terminated

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07424027 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07424027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing